08:38 AM EDT, 06/17/2025 (MT Newswires) -- ProPhase Labs ( PRPH ) said Tuesday its BE-Smart molecular diagnostic test achieved over 95% success in detecting biomarkers linked to esophageal cancer, validating its use with esophageal brush cytology.

The test, using a proprietary panel of biomarkers, reliably detects cancer cells, particularly in esophageal adenocarcinoma, a rapidly growing cancer, the company said.

BE-Smart has now been validated for both brush and forceps biopsies, providing a tool for comprehensive esophageal disease surveillance.

The company said it plans to accelerate the commercialization of BE-Smart with a clinical launch expected in the next two to three quarters, targeting a $10 billion market.

Shares of the company rose more than 11% in recent Tuesday pre-bell activity.

Price: 0.3685, Change: +0.036, Percent Change: +11.21